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Tümör Kütlesi Oluşumuna Etkisi
Meltem Elitas
GlİoMA-MAkRofAj EtkİlEşİMİnİn tüMöR kütlEsİ oluşuMunA Etkİsİ
özEt
Tümör mikroçevresi glioma hücreleri ve bağışıklık sistemi hücreleri arasındaki etkileşimi değiştirmektedir. Bu 
çalışma makrofajların glioma hücrelerine çoğalma ve invazyonu kolaylaştıran yeni fenotipik özellikler kazandır-
dığını göstermektedir.
Anahtar sözcükler: Glioma, makrofaj, mikroakışkanlar ve niceliksel veriler.
AbstRACt
Tumor microenvironment alters the interactions between glioma cells and immune cells. This study shows that 
immune cells gain new phenotypic properties that are believed to facilitate the proliferation rate and invasiveness 
of glioma cells. 
key words: Glioma, macrophage, microfluidics, and quantitative data.
Glioblastoma multiform (GBM) is one of the most deadly tumors , commonly seen in children and adults over the age of fifty (1). The survival of patients could be extended up to 15 months with treatment of chemotherapy, radi-
ation and surgery (2, 3, 4). One of the biggest difficulties during diagnosis , is that 
the symptoms of the disease are difficult to determine until tumor effects on brain 
functions are visible. The diagnostic phase is based on magnetic resonance imaging 
(MRI). However, MRI cannot provide very precise results in many cases; therefore, exa-
mination of the biopsy sample is required to determine extent +of the tumor (5). 
One of the biggest problems in the treatment stage is that cells in the brain are very 
sensitive to chemotherapeutic reagents. Likewise, the blood-brain barrier prevents 
effective delivery of nanoparticles and drugs (6). In addition to all these challenges, 
GBM spreads very aggressively even though a successful surgical removal of the pri-
mary tumor is achieved; “secondary tumors” may occur.
Since 1926, researchers have been investigating the intense heterogeneity in GBM 
and its effects on diagnosis and treatment of GBM (7, 8). Today, recent studies related 
to GBM heterogeneity have pointed to the interactions between the immune sys-
tem cells and cancer cells (9, 10, 11). Tumor microenvironment alters the interaction 
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of glioma cells and immune system cells, as a result, s the 
immune cells gain new phenotypic properties that are be-
lieved to facilitate the growth and spread of tumor cells 
(9, 12). Tumor-associated macrophages (TAMs) have been 
shown to promote malignant glioma growth by creating a 
local immunosuppressive microenvironment (13), secret-
ing pro-angiogenic factors and enhancing invasion medi-
ated by the production of soluble factors such as colony 
stimulating factor-1 (CSF-1), transforming growth factor-β 
(TGF-β), interleukin (IL)-10, vascular endothelial growth 
factor, and matrix metallopeptidase-9 (14, 15). In glioblas-
toma, TAMs can comprise up to 40% of all cells in GBM the 
high-grade gliomas having the higher number of macro-
phages compared to low-grade gliomas (16, 17, 18). These 
findings encouraged us to perform glioma-macrophage 
co-culture experiments using microfluidic devices in or-




The U-87 MG (HTB-14) human glioma and the U937 hu-
man monocytes were purchased from ATCC (American 
Type Culture Collection). 10 ml of the U937 human mono-
cyte cell line was stimulated with 0.5 µL 1 µg/mL phor-
bol 12-myristate 13-acetate (PMA/Fisher) according to 
standard protocols for macrophage differentiation. Cells 
were grown at 37˚C with 5% CO2. The U-87 cells were de-
tached with Trypsin-EDTA (0.25%) (Gibco, Invitrogen) and 
maintained in MEM medium (Gibco, Invitrogen), 10% fetal 
bovine serum (FBS/ATCC). The immune cell lines were cul-
tured in RPMI 1640 medium (Gibco, Invitrogen), 10% FBS 
(ATCC).
Fluorescent probe staining
U-87 and U937-differentiated macrophages were grown 
via standard procedure for 4 days. The cells were detached 
using trypsin, harvested by centrifugation, and their su-
pernatant was removed. The macrophages were resus-
pended in pre-warmed green Dil lipophilic tracker solu-
tion for subsequent identification (Lipophilic Tracers—Dil, 
DiO, DiD, DiA, and DiR, INVITROGEN). Solution of lipophilic 
tracers were dissolved in research-grade DMSO (Dimethyl 
sulfoxide) to a final concentration of 10mM). The final 
working concentration of cell suspension, including dye 
was 25 µM in fresh medium. The cells were incubated 
for 1 hour in a standard tissue incubator. Subsequently, 
the cells were collected by centrifugation. The dye solu-
tion was replaced with fresh medium. This washing step 
was repeated gently three times with fresh medium. Cell 
viability, proliferation and functionality were not affected 
by lipophilic tracker dyes compared to non-fluorescence 
labeled cells (data not shown).
Imaging and data analysis
Glioma cells, macrophages and their mixture were grown, 
respectively, in the culture and co-culture wells, imaged 
with motorized fluorescence microscope (Nikon Eclipse). 
In the co-culture wells, prior to the experiment, macro-
phage cells were stained with green live cell tracker dyes 
(CMFDA, Invitrogen) and FITC channel was merged to 
phase channel to distinguish them from the glioma tu-
mor cells. A motorized stage (Prior, Proscan III) was used 
to collect an array of images and stitched them using 
Elements software (Nikon) in order to visualize the whole 
microchamber. 
Next, the images were used to quantify the number, 
area and spatial location of the tumor spheres in the mi-
crowells. Tumor-sphere analysis was achieved using the 
Elements image processing software (Nikon), manually 
the periphery of the tumor spheres were contoured and 
their area were measured.
The extracted data was compiled and graphics were ob-
tained using Prism 5 software (GraphPad).
Results
In this study, glioma U-87 cells, U937-differentiated mac-
rophages and their co-culture were performed in 6-well 
plates for 7 days as illustrated in Figure 1. 60 000 glioma 
cells, 120 000 macrophages and their co-culture with 60 
000 glioma cells and 120 000 macrophages were inocu-
lated as explained in the material and methods chapter. 
The number of macrophages was twice more than the 
number of glioma cells in the co-culture wells due to the 
fact that macrophages cannot proliferate. We obtained 
microscope images of each well everyday for 7 days. After 
imaging, we replaced half of the medium from the wells 
with the fresh medium to decrease the waste product of 
the cells and to provide nutrients to the cells. Then, the 
6-well plate was directly placed into the incubator. The 
growth difference between the glioma alone and glio-
ma-macrophage co-culture well is presented in Figure 2. 
The tumor spheres were marked with the green line us-
ing the microscope software to measure their areas and 
count their numbers. Figure 2a shows glioma-alone cul-
ture, Figure 2b presents glioma-macrophage co-culture. 
The number of tumor spheres is demonstrated in Figure 3. 
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Figure 1. Co-culture experiments for glioma sphere fotmation
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Figure 3. Number of tumor spheres and their area measurements in glioma 
alone and glioma-macrophage co-culture wells after 7-day culturing.
Figure 4. Histogram of the area distribution of tumor-spheres for glioma alone 
culture and glioma-macrophage co-culture. 
Figure 4 illustrates the area distribution of tumor spheres 
in glioma alone and glioma-macrophage co-culture wells. 
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